SILENCE THERAP. SP.ADR/1 Total Liabilities

Latest as of December 2025: €69.14 Million EUR ≈ $80.83 Million USD

SILENCE THERAP. SP.ADR/1 total liabilities. Based on the latest financial reports, SILENCE THERAP. SP.ADR/1 (XRP2) has total liabilities worth €69.14 Million EUR (≈ $80.83 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of SILENCE THERAP. SP.ADR/1 to evaluate the company's liquid asset resilience ratio.

Total Liabilities of SILENCE THERAP. SP.ADR/1 (2021–2025)

Total liabilities of SILENCE THERAP. SP.ADR/1 from 2021 to 2025. This chart illustrates how SILENCE THERAP. SP.ADR/1's total liabilities have evolved over time, based on quarterly financial data. Explore XRP2 long-term investments to assets to see how much of total assets are deployed in long-term investments.

SILENCE THERAP. SP.ADR/1 Competitors by Total Liabilities

The table below lists competitors of SILENCE THERAP. SP.ADR/1 ranked by their total liabilities.

Company	Country	Total Liabilities
J.G.CHEMICALS LIMITED NSE:JGCHEM	India	Rs282.86 Million
Air Asia Co Ltd TW:2630	Taiwan	NT$2.24 Billion
888 Holdings plc F:C8V	Germany	€2.77 Billion
Sichuan Tianwei Electronic Co Ltd SHG:688511	China	CN¥108.99 Million
Somany Ceramics Limited NSE:SOMANYCERA	India	Rs10.41 Billion
CSLM Digital Asset Acquisition Corp III, Ltd NASDAQ:KOYN	USA	$10.08 Million
Kcc Glass Corp KO:344820	Korea	₩1.07 Trillion
Journey Energy Inc TO:JOY	Canada	CA$221.38 Million

Liability Composition Analysis (2021–2025)

This chart breaks down SILENCE THERAP. SP.ADR/1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see XRP2 current and non-current assets.

Liquidity & Leverage Metrics

SILENCE THERAP. SP.ADR/1 Total Liabilities Ratios Explained

SILENCE THERAP. SP.ADR/1 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	8.72	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	1.11	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.53	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how SILENCE THERAP. SP.ADR/1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for SILENCE THERAP. SP.ADR/1 (2021–2025)

The table below shows the annual total liabilities of SILENCE THERAP. SP.ADR/1 from 2021 to 2025.

Year	Total Liabilities	Change
2025-12-31	€69.14 Million ≈ $80.83 Million	+0.77%
2024-12-31	€68.61 Million ≈ $80.21 Million	-29.60%
2023-12-31	€97.45 Million ≈ $113.94 Million	-5.74%
2022-12-31	€103.38 Million ≈ $120.87 Million	-12.62%
2021-12-31	€118.32 Million ≈ $138.33 Million	--

About SILENCE THERAP. SP.ADR/1

F:XRP2 Germany Biotechnology

Market Cap

$386.55 Million

€330.64 Million EUR

Market Cap Rank

#15500 Global

#1513 in Germany

Share Price

€7.00

Change (1 day)

+10.24%

52-Week Range

€2.70 - €7.00

All Time High

€26.80